Rocket Lab shares slump 13% as Neutron rocket launch delayed to 2027

Rocket Lab shares fell 13% to $51.42 on Thursday after the company delayed Neutron’s maiden flight until 2027, from its prior fourth-quarter 2026 target. The delay follows manufacturing problems with the rocket’s first-stage propellant tank.

Analysis

The key change is not simply a later launch date: it raises the risk that Neutron converts from a near-term growth catalyst into a longer period of engineering spend before commercial validation. That can compress RKLB’s valuation even if its existing launch and space-systems activities remain operationally separate; the relevant offset is their cash generation and backlog, which should be checked rather than assumed to fund the delay. Repeated schedule slippage also gives customers and prospective partners reason to preserve alternatives, strengthening the negotiating position of established providers such as SpaceX and competing launch developers.

Over days, the sharp repricing may already capture much of the schedule news, while elevated volatility makes outright puts costly. Over 1–3 months, the evidence that matters is not another target date but measurable progress on the tank, updated spending/cash guidance, and whether management’s milestones become more credible. Over 6–18 months, further slippage could defer Neutron-related revenue and weaken the growth narrative; successful qualification and a stable funding profile would reverse that pressure. The contrarian case is that the market may be over-penalizing a development program while discounting the existing business, but that case requires segment-level cash-flow and backlog data. No valuation or funding conclusion is supportable from the reported delay alone.

Key Decisions for Investors

• Avoid chasing a fresh short immediately after the gap down. If RKLB fails to stabilize and management cannot demonstrate concrete tank-manufacturing progress, consider a defined-risk bear call spread after implied volatility settles; cap exposure because a credible recovery update could trigger a sharp squeeze.
• Treat RKLB as a catalyst-driven watch rather than an automatic long-term thesis break. Before adding, verify cash and liquidity, capex and operating cash-flow guidance, segment backlog, and whether Neutron spending is changing; these determine whether delay creates financing risk or primarily defers upside.
• Use milestone quality as the 1–3 month signal: downgrade the thesis on another schedule slip, worsening cash guidance, or vague engineering updates; reconsider a long only on verifiable production/qualification progress alongside stable funding metrics.
• Do not extrapolate this delay to Electron or all of Rocket Lab’s business. For relative-value work, compare launch alternatives including SpaceX and other launch developers, but size any pair only after checking customer overlap, contract timing, and each company’s disclosed capacity.